β-Arrestin-2 counters CXCR7-mediated EGFR transactivation and proliferation

Molecular Cancer Research

Volumn 14, Issue 5, 2016, Pages 493-503

  Kallifatidis, Georgios ^a   Munoz, Daniel ^b   Singh, Rajendra Kumar ^e   Salazar, Nicole ^f,g   Hoy, James J ^c   Lokeshwar, Bal L ^a,d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e DOW CHEMICAL COMPANY   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BETA ARRESTIN 2; CHEMOKINE RECEPTOR CXCR7; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P21; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; ARRB2 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CXCR; CXCR7 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE TARGETING; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; MITOGENESIS; PRIORITY JOURNAL; PROSTATE EPITHELIUM CELL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSACTIVATION; CELL LINE; CYTOLOGY; EPITHELIUM CELL; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PROSTATE TUMOR;

BETA-ARRESTIN 2; CELL LINE; CELL PROLIFERATION; EPITHELIAL CELLS; GENE KNOCK-IN TECHNIQUES; GTP-BINDING PROTEINS; HUMANS; MALE; MUTATION; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CXCR; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84969130046     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0498     Document Type: Article

References (27)

1. Salazar N, Castellan M, Shirodkar SS, Lokeshwar BL. Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit Rev Eukaryot Gene Expr 2013; 23:77-91.
2. Sanchez-Martin L, Sanchez-Mateos P, Cabanas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol Med 2013; 19:12-22.
3. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203:2201-13.
4. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283:4283-94.
5. Hattermann K, Held-Feindt J, Lucius R, Muerkoster SS, Penfold ME, Schall TJ, et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010; 70:3299-308.
6. Singh RK, Lokeshwar BL. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 2011; 71:3268-77.
7. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, et al. Beta-Arrestinbut notGprotein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A 2010; 107:628-32.
8. MaL, PeiG. Beta-Arrestin signaling and regulation of transcription. JCell Sci 2007; 120213-8.
9. Buchanan FG, DuBois RN. Emerging roles of beta-Arrestins. Cell Cycle 2006; 5:2060-3.
10. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-Arrestins and cell signaling. Annu Rev Physiol 2007; 69:483-510.
11. Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, et al. b-Arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene 2012; 31:282-92.
12. Zhang P, He X, Tan J, Zhou X, Zou L. b-Arrestin2mediates beta-2 adrenergic receptor signaling inducing prostate cancer cell progression. Oncol Rep 2011; 26:1471-7.
13. Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM. Depletion of beta-Arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2008; 180:5699-706.
14. Salazar N, Munoz D, Kallifatidis G, Singh RK, Jorda M, Lokeshwar BL. The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation. Mol Cancer 2014; 13:198.
15. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral nonantimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002; 98:297-309.
16. Lokeshwar BL, Lokeshwar VB, Block NL. Expression of CD44 in prostate cancer cells: Association with cell proliferation and invasive potential. Anticancer Res 1995; 15:1191-8.
17. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009; 113:6085-93.
18. Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, Minina S, et al. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008; 132:463-73.
19. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 2007; 104:14759-64.
20. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884-8.
21. Pierce KL, Tohgo A, Ahn S, Field ME, Luttrell LM, Lefkowitz RJ. Epidermal growth factor (EGF) receptor-dependent ERK activation by G proteincoupled receptors: A co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. J Biol Chem 2001; 276:23155-60.
22. Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, et al. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer 2013; 81:138-41.
23. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 2006; 95:211-8.
24. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3:802-8.
25. Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiother Oncol 2013; 108:370-7.
26. Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 2011; 12:419-32.
27. Kuo FT, Lu TL, Fu HW. Opposing effects of beta-Arrestin1 and betaarrestin2 on activation and degradation of Src induced by protease-Activated receptor 1. Cell Signal 2006; 18:1914-23.